Twin Cities metro fails air pollution report card
Why it matters: Air pollution threatens everyone's health — especially children, seniors and people with asthma or heart and lung conditions.
The big picture: Nearly half of Americans are now exposed to potentially dangerous levels of air pollution, the American Lung Association's 2025 State of the Air report found.
State of play: The report, which looked at 200-plus large cities, dinged the Twin Cities as one of the 40 worst metro areas in the nation for 24-hour particle pollution.
The area ranked 48th for the number of high-ozone days.
Zoom in: Hennepin, Ramsey and Dakota counties got an F for particle pollution.
The report also gave Anoka and Scott counties failing grades for ozone levels.
Context: Ozone is a gas that, at ground level, is a harmful irritant. Particle pollution involves tiny airborne particles from wildfires, fossil fuel burning and more.
Threat level: Extreme heat, wildfires and drought are degrading air quality nationwide, the Lung Association says. All have been linked to climate change.
Air pollution is associated with an array of health conditions, from wheezing and coughing to asthma and premature death.
Between the lines: This latest report includes data from 2021-23, "the most recent three years of quality-assured nationwide air pollution data publicly available."
2023 was a particularly bad year for Minnesota air quality, due to wildfire smoke from Canada.
The silver lining: The Duluth metro area earned kudos from the report, ranking 15th on the report's list of top 25 cleanest cities for particle pollution.
What we're watching: The findings, which predate the current Trump administration, come as the White House is reconsidering EPA rules and regulations meant to curb pollution and promote cleaner air.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
40 minutes ago
- CNN
Trump to launch effort to ease Americans' access to their medical records — but privacy concerns loom
Donald TrumpFacebookTweetLink Follow President Donald Trump on Wednesday will make a fresh push to improve Americans' access to their own medical records, tasking dozens of major health and technology companies with solving an issue that has long bedeviled the federal government. The plan is expected to center on a pledge that roughly 60 companies will sign — including tech giants Microsoft and Oracle — to help develop new ways for more easily sharing patient data across the US's fragmented health care system, three people familiar with the matter told CNN. Trump is slated to tout the voluntary framework during a White House speech on Wednesday. Yet it remains unclear how quickly the companies can make progress on such a sweeping goal — and how the administration plans to hold them accountable for following through on the high-level, nonbinding commitment. The proposal may also spark pushback from privacy advocates who have warned that making patients' sensitive health data more widely accessible risks also making it less secure. The Centers for Medicare and Medicaid Services, which oversees the largest federal health programs, declined to comment on the details of the announcement. But in a statement, spokesperson Catherine Howden said the 'initiative aims to build a smarter, more secure and more personalized healthcare system — one that improves patient outcomes, reduces provider burden and drives greater value through private sector innovation and aligned federal leadership.' Bloomberg News first reported some of the initiative's details. The move represents the latest in a long line of attempts by the federal government to give patients greater access and control over their own health records, which often don't smoothly transfer from one health provider to another. Meanwhile, there's a newly added benefit for Silicon Valley, which has heavily invested in a growing array of consumer health, wellness and artificial intelligence startups that stand to gain from users being able to more seamlessly download their data and direct it to the apps of their choice. Amy Gleason, the acting administrator of DOGE and a former health tech executive, and Arda Kara, who worked at big data firm Palantir before joining the Trump health department, have led the medical records push, two of the people familiar said. The pledge comes two-and-a-half months after the health department issued a request for input from health and tech companies for improving the nation's 'digital health ecosystem.' Past Democratic and Republican administrations have made improving health record access a policy priority, arguing that it's critical to providing patients with better and more efficient care. But progress in Congress and within the federal government has been slowed by the thicket of technical challenges and privacy considerations surrounding Americans' most sensitive health data. Trump officials are planning to try a different route, relying on the private sector to make headway on those thorny problems ahead of any significant government intervention, the people familiar said. The tactic mirrors the hands-off approach the administration has taken on other top health priorities, such as encouraging food companies to voluntarily remove artificial dyes from products and getting insurers to commit to improving a 'prior authorization' process often blamed for delaying patients' care. But overhauling health records access will likely require broad collaboration among competitors across the health and technology industries, raising questions about whether the private sector will be able to agree on a host of minute details with broad implications. Plus, previous pushes have prompted significant concerns among privacy advocates and some parts of the health industry. Those groups worried that giving Americans greater ability to share their records will undermine federal efforts to keep their information private, making it easier for people to unwittingly expose their most sensitive data to companies with poor security or bad intentions, which could profit by selling that data.
Associated Press
43 minutes ago
- Associated Press
Global Kratom Coalition Applauds HHS Crackdown on Dangerous Synthetic Kratom Derivatives
New federal action targets 7-hydroxymitragynine products, while protecting access to natural kratom leaf The Global Kratom Coalition (GKC) today applauded the U.S. Department of Health and Human Services (HHS) for taking decisive action to protect public health by moving to schedule products that contain high concentrations of 7-hydroxymitragynine (7-OH or '7'). Scheduled drugs are those with a high potential for abuse, with no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The announcement, made by Health Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, targets manipulated, high-potency, synthetic products like '7' that are opioids masquerading as dietary supplements and are being sold online and in smoke shops across the country. The introduction of these products in the last two years has raised alarm among public health experts and responsible kratom advocates alike, who warn that these synthetic products pose a serious risk to consumers and undermine the safe, traditional use of kratom leaf. 'The Department of Health and Human Services is showing bold, science-driven leadership by taking aim at these rogue 7-OH products,' said Walker Gallman, legislative director of the Global Kratom Coalition. 'Secretary Kennedy and Commissioner Makary deserve enormous credit for drawing a clear line between dangerous synthetics and the natural plant. This is a huge win for public health and for millions of Americans who responsibly use leaf kratom to improve their quality of life.' HHS made clear that natural leaf kratom is not the target of this action. Federal officials have rightly distinguished between the traditionally used botanical with centuries of safe use and synthetic derivatives like '7,' which pose significant health risks due to their potency and opioid-like effects. This distinction is critical to protect public health while preserving access to natural kratom for the millions of Americans who use it safely and responsibly. Today's announcement follows FDA actions taken earlier this month. The FDA has already begun ramping up enforcement, issuing seven warning letters to manufacturers of 7-OH products. This action sets the stage for stronger measures ahead, including potential product seizures and civil penalties. Today's announcement also featured strong support from Sen. Markwayne Mullin (R-Okla.), who has been an advocate for distinguishing natural leaf kratom from synthetic opioids, as well as powerful testimony from natural leaf kratom consumer Melody Woolf of Kalamazoo, Michigan. Woolf, a longtime advocate for natural kratom, described how natural kratom leaf helped her in her daily life but warned that synthetic 7-OH products represent a dangerous and misleading alternative. 'It was only the powdered kratom leaf that saved my life,' Woolf testified. 'Now I'm seeing something very dangerous happen. 7-OH is being sold over the counter, and it's not the plant. It's concentrated and addictive. People think it's kratom, but it's not. And it's dragging some back toward opioid use. 7-OH needs to be off the shelves.' Gallman added, 'Melody's story is one of thousands. She represents what we're fighting for—access to natural, responsibly regulated kratom. We applaud HHS for standing with consumers like her and protecting them from deceptive, dangerous knockoffs.' The Global Kratom Coalition encourages HHS to work closely with the Drug Enforcement Administration (DEA) to move swiftly through the federal scheduling process for synthetically derived 7-hydroxymitragynine products. Coordinated action is essential to ensure these dangerous, highly concentrated substances are removed from the market before they can cause further harm. By partnering on enforcement and regulation, HHS and DEA can protect consumers while preserving access to safe, natural kratom leaf. About Global Kratom Coalition The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit Media Contact Patrick George +1 916-202-1982 [email protected] ### SOURCE: Global Kratom Coalition Copyright 2025 EZ Newswire
CNN
44 minutes ago
- CNN
‘Ozempic face' may be driving a cosmetic surgery boom
About two years ago, celebrity cosmetic dermatologist Dr. Paul Jarrod Frank noticed a new type of patient arriving at his New York practice. Amid an explosion in the number of Americans losing weight with drugs like Ozempic, he saw a 'dramatic spike' in clients experiencing unwelcome side effects. 'Although they felt much better losing weight, in some ways they felt they looked older,' he said via a voice note. 'And this was due to the loss of volume in their face.' Frank started using the term 'Ozempic face' — a label he believes he coined — to describe the phenomenon. It has since become a social media byword for the sagging skin and hollowed-out appearance that can accompany the use of GLP-1 medications like semaglutide (the active ingredient in branded drugs such as Ozempic and Wegovy). 'Usually, with people from their mid-40s and above, once you start losing 10-plus pounds, you can get this kind of deflated look,' said Frank, who is the founder of aesthetic health care brand PFRANKMD and the author of 'The Pro-Aging Playbook.' 'Certainly, people losing 20 or 30-plus pounds are going to have this problem.' 'You can only refill a deflated balloon so much, and often surgical intervention is necessary.' Dr. Paul Jarrod Frank Semaglutide works by stimulating the pancreas to trigger insulin production, curbing users' appetite and contributing to feelings of fullness. Although the US Food and Drug Administration approved Ozempic to treat type 2 diabetes, doctors now commonly prescribe it off-label for weight management. About 1 in 8 adults in the US has used a GLP-1 drug, and of those, around 2 in 5 did so solely to lose weight, according to health policy non-profit KFF in 2024. Today, more than 20% of Frank's patients are using GLP-1s as part of what he called their 'longevity regimen.' The treatments sought after their weight loss include injectable dermal fillers to help restore facial volume, facelifts and fat transfers. 'You can only refill a deflated balloon so much, and often surgical intervention is necessary,' he said. But for many patients, he added, 'just upping the dosage of their volume replacement is more than enough. 'Someone who may have used one syringe of filler in the past is now using two or three.' The American Society of Plastic Surgeons (ASPS), which publishes an annual report on surgery trends, recently found that 2 in 5 of its members' GLP-1 patients were considering undergoing cosmetic surgery — and 1 in 5 already had. Among the patients opting for a facelift was Kimberly Bongiorno, a local government land use administrator from Mount Arlington, New Jersey. Having lost weight after gastric sleeve surgery in 2019, she regained 40 pounds during the Covid-19 pandemic and was prescribed Wegovy last year. Despite describing the drug's impact as 'almost a miracle' — taking her weight from 170 to 125 pounds — the 55-year-old faced new concerns over her appearance. 'Everything just kind of hung and was very loose,' she said over Zoom, recalling seeing her face in a photo shared by a friend. 'I no longer felt like I had cheeks, and I had a lot of loose skin under my neck. 'It looked like I had melted. It was horrifying,' she added. 'It was so disheartening to see how my face looked and how it had changed, I thought I looked a lot older than I am.' After consulting plastic surgeon Dr. Anthony Berlet at his New Jersey office, Bongiorno underwent a deep plane facelift that lifted her skin and repositioned some of the deeper muscles and connective tissues. She also opted for a neck lift that refined and smoothed her neck contours while addressing excess skin left by her weight loss. 'Before I did this, I probably looked closer to 60, or maybe even older. And now I have people who I've recently met think I am in my 40s,' Bongiorno said, adding: 'People I haven't seen in a while say, 'You look so healthy and happy.' And that's nice to hear, because for a while, I didn't look healthy and certainly wasn't happy.' The number of facelifts performed in the US jumped 8% between 2022 and 2023, according to ASPS data. The use of hyaluronic acid fillers has meanwhile doubled from 2.6 million Americans in 2017 — the year Ozempic was first cleared for diabetes — to over 5.2 million in 2023. The organization could not attribute these upticks exclusively to GLP-1 use, but its former president, Dr. Steven Williams, said the medications have had 'a global effect on aesthetic surgery.' 'Now we have a brand-new tool that actually has efficacy for so many patients,' said Williams, a board-certified plastic surgeon and founder of California's Tri Valley Plastic Surgery, over Zoom. He noted that GLP-1s come 'without substantial drawbacks' when compared with invasive procedures like gastric bypass surgery. 'We can now have an honest conversation with patients about a nonsurgical tool that's effective in weight loss,' he added. 'And as part of that conversation, there's an obligation to say, 'Look, this is really going to work, so you have to be prepared for what looking 20 or 50 pounds slimmer is going to be.'' The term 'Ozempic face' may speak to our times, but its symptoms — caused by a decrease in the subcutaneous fat that makes our faces plump — are nothing new. Cosmetic surgeons have long been treating the side effects of significant weight loss. In fact, one popular brand of dermal filler, Sculptra, was originally developed in the 1990s for HIV patients. As an adult, 'your body actually doesn't make more fat cells,' Williams said. 'As we lose or gain weight, those fat cells aren't multiplying or decreasing; they're getting bigger or smaller. And so as we lose weight, those fat cells now have decreased volume, and there's just less fullness.' Age can determine how patients' faces react to weight loss. People in their 20s and 30s, for instance, are far less likely to experience the appearance of aging due to GLP-1 use, Frank said. 'Because they have good skin elasticity, the skin rebounds much better,' he said. Patients aged 20 to 39 accounted for 14% of hyaluronic acid filler use in the US and just 2% of facelift procedures last year, according to the ASPS. But both figures are on the rise. Gabriela Vasquez, 29, is among the younger patients using GLP-1 to undergo cosmetic procedures after rapid weight loss. An employee of one of Williams' Tri Valley Plastic Surgery clinics, she has dropped around 50 pounds since starting Ozempic in November. Although Vasquez is still working toward her target weight, she sought preventative Botox injections (more visible lines and wrinkles are, along with thinning lips, among the other side effects of GLP-1 use). She has also recently undergone microneedling, a procedure used to stimulate collagen production. 'One of my concerns was my jowls, because I felt I saw them when I was a little heavier,' she said over Zoom from the Bay Area. 'I think the microneedling definitely helped. 'I never had a jaw line,' she added. 'And a couple weeks ago, someone took a picture of me, and I had one, and I was like, 'Well, that's new.'' Vasquez did not rule out further cosmetic procedures as she continues losing weight — and not only to her face and neck. 'I'm seeing little things in my body that I'm like, 'Whoa, that would be nice to take care of,'' she said, referencing the appearance of excess skin under her arms. 'I could see myself — later down the line, once I get to my goal weight — doing something to kind of tighten everything up.' Frank, the cosmetic dermatologist, noted that 'Ozempic face' may be accompanied by a phenomenon he dubbed 'Ozempic body,' adding: 'One of the other major side effects of weight loss, particularly when it's done at a rate of more than one to two pounds a week, is muscle loss. And we see this all over the body.' The ASPS similarly notes the emerging term 'Ozempic makeover,' a suite of procedures that might also include tummy tucks, breast lifts and arm, thigh and buttock lifts. For instance, Bongiorno, the New Jersey facelift patient, has also undergone several other procedures with Dr. Berlet, including arm and thigh lifts, to address her excess skin. She estimates that after her upcoming breast lift, fat grafting and lower eyelid surgery, she will have spent about $80,000 on cosmetic procedures. 'Skin is heavy and uncomfortable,' she said. 'This wasn't something I did to go out there and be a supermodel. It was just to be comfortable, so I could get clothes on and not feel like I was dragging around all this extra weight.' The long-term effect of GLP-1 medications on cosmetic medicine is yet to be fully understood. The assumption they might reduce demand for liposuction, for instance, has not come to bear: It remains the most common cosmetic surgical procedure in the US, growing in popularity by 1% last year, per ASPS data. What also remains to be seen is the effect that 'Ozempic rebound' — when patients regain weight after stopping the drugs — has on people who sought cosmetic procedures. A recent peer-reviewed study found that most people using the drugs for weight loss quit within a year. Data presented at this year's European Congress on Obesity meanwhile suggested that patients typically returned to their original weight within 10 months of stopping use, with University of Oxford researchers calling the findings a 'cautionary note' about using medication 'without a more comprehensive approach' to weight loss. For Williams, this further demonstrates why he and his plastic surgeon colleagues must take responsibility for their patients' 'entire journey,' not just their cosmetic procedures. 'We don't want these patients to be on these medications for a lifetime. We want it to be a temporary bridge to a healthier lifestyle,' he said, adding: 'It's our obligation to work harder with those patients, to talk about lifestyle changes, to get them plugged in to dietitians and to make sure that they're building muscle and exercising.'
